Ibandronate treatment in Paget's disease of bone.

[1]  A. Grauer,et al.  Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. , 2000, Clinical chemistry.

[2]  P. Delmas,et al.  MANAGEMENT OF PAGET’S DISEASE OF BONE , 1978 .

[3]  J. Body,et al.  Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  D. Thiebaud,et al.  Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. , 1996, Bone.

[5]  P. Meunier,et al.  Therapeutic strategy in Paget's disease of bone. , 1995, Bone.

[6]  A. Grauer,et al.  Long-term efficacy of intravenous pamidronate in Paget's disease of bone. , 1994, Seminars in arthritis and rheumatism.

[7]  C. Coupland,et al.  Determinants of remission of paget's disease of bone , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  M. Ghielmini,et al.  Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. , 1993, Bone and mineral.

[9]  F. Bauss,et al.  BM 21.0955, a potent new bisphosphonate to inhibit bone resorption , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  D H COLLINS,et al.  PAGET'S DISEASE OF BONE: INCIDENCE AND SUBCLINICAL FORMS , 1956 .

[11]  B. Thürlimann,et al.  Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. , 1997, British Journal of Cancer.

[12]  B. Thürlimann,et al.  Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.